PL2049127T3 - N-metanokarbapochodne do leczenia chorób serca - Google Patents

N-metanokarbapochodne do leczenia chorób serca

Info

Publication number
PL2049127T3
PL2049127T3 PL07777211T PL07777211T PL2049127T3 PL 2049127 T3 PL2049127 T3 PL 2049127T3 PL 07777211 T PL07777211 T PL 07777211T PL 07777211 T PL07777211 T PL 07777211T PL 2049127 T3 PL2049127 T3 PL 2049127T3
Authority
PL
Poland
Prior art keywords
cardiac diseases
treat cardiac
methanocarba derivatives
methanocarba
derivatives
Prior art date
Application number
PL07777211T
Other languages
English (en)
Inventor
Bruce Tsan Liang
Achilles Pappano
Jian-Bing Shen
Original Assignee
Univ Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Connecticut filed Critical Univ Connecticut
Publication of PL2049127T3 publication Critical patent/PL2049127T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL07777211T 2006-05-23 2007-05-22 N-metanokarbapochodne do leczenia chorób serca PL2049127T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80287806P 2006-05-23 2006-05-23
US89394607P 2007-03-09 2007-03-09
EP07777211.9A EP2049127B1 (en) 2006-05-23 2007-05-22 N-methanocarba derivatives to treat cardiac diseases
PCT/US2007/012151 WO2007139775A2 (en) 2006-05-23 2007-05-22 N-methanocarba derivatives to treat cardiac diseases

Publications (1)

Publication Number Publication Date
PL2049127T3 true PL2049127T3 (pl) 2015-03-31

Family

ID=38596738

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07777211T PL2049127T3 (pl) 2006-05-23 2007-05-22 N-metanokarbapochodne do leczenia chorób serca

Country Status (7)

Country Link
US (1) US8410078B2 (pl)
EP (1) EP2049127B1 (pl)
DK (1) DK2049127T3 (pl)
ES (1) ES2526713T3 (pl)
PL (1) PL2049127T3 (pl)
PT (1) PT2049127E (pl)
WO (1) WO2007139775A2 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11346797B2 (en) 2002-12-20 2022-05-31 Agilent Technologies, Inc. System and method for monitoring cardiomyocyte beating, viability, morphology and electrophysiological properties
CA2720037C (en) 2008-03-31 2016-08-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as a3 adenosine receptor-selective agonists
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
WO2009137440A1 (en) 2008-05-05 2009-11-12 Acea Biosciences, Inc. Label-free monitoring of excitation-contraction coupling and excitable cells using impedance based systems with millisecond time resolution
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
CA2732320C (en) 2008-08-01 2017-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
ES2654363T3 (es) * 2010-02-22 2018-02-13 University Of Connecticut Derivados de AMP para tratar enfermedades cardíacas
US9681836B2 (en) 2012-04-23 2017-06-20 Cyberonics, Inc. Methods, systems and apparatuses for detecting seizure and non-seizure states
WO2014170343A1 (en) 2013-04-15 2014-10-23 Icm (Institut Du Cerveau Et De La Moelle Épinière) Depolarizing agents and nicotinic acetylcholine receptor modulators for treating dopaminergic-related disorders
US10195198B2 (en) 2014-07-03 2019-02-05 Afferent Pharmaceuticals, Inc. Methods and compositions for treating diseases and conditions
WO2017185061A1 (en) 2016-04-21 2017-10-26 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions
US11746328B2 (en) 2017-03-03 2023-09-05 Agilent Technologies, Inc. Methods and systems for functional maturation of iPSC and ESC derived cardiomyocytes
JP7311855B2 (ja) 2018-02-09 2023-07-20 アストロサイト ファーマシューティカルズ， インコーポレイテッド 嗜癖および関連する障害を処置するための化合物および方法
WO2020069068A1 (en) 2018-09-26 2020-04-02 Astrocyte Pharmaceuticals, Inc. Polymorphic compounds and uses thereof
USD941488S1 (en) 2020-02-07 2022-01-18 Agilent Technologies, Inc. Instrument for analyzing biological cells
US20210301245A1 (en) 2020-03-29 2021-09-30 Agilent Technologies, Inc. Systems and methods for electronically and optically monitoring biological samples
WO2025024312A1 (en) * 2023-07-21 2025-01-30 Cornovus Pharmaceuticals, Inc. Aqueous formulations of a cardiac p2x receptor agonist and their use in treating medical disorders
US20250368668A1 (en) * 2024-06-03 2025-12-04 Cornovus Pharmaceuticals, Inc. Crystalline forms and salt forms of a cardiac p2x receptor agonist, pharmaceutical compositions, and their use in treating medical disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712258A (en) 1995-03-23 1998-01-27 The Trustees Of The University Of Pennsylvania Inotropic ADP and ATP analogues and their pharmaceutical compositions
US7348315B2 (en) 1995-03-23 2008-03-25 The University Of Connecticut Methods of treating heart failure with modified ATP, ADP and AMP compounds
WO1999020284A1 (en) 1997-10-23 1999-04-29 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid a and adenosine receptor agents
EP1872797A3 (en) * 1999-08-24 2008-04-02 Medicure International Inc. Treatment of cardiovascular and related pathologies
US6586413B2 (en) 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
EP1252160B1 (en) 2000-01-14 2006-08-16 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Methanocarba cycloalkyl nucleoside analogues
EP1794162A1 (en) 2004-09-09 2007-06-13 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Purine derivatives as a3 and a1 adenosine receptor agonists

Also Published As

Publication number Publication date
PT2049127E (pt) 2014-12-23
US8410078B2 (en) 2013-04-02
WO2007139775A3 (en) 2008-01-24
EP2049127A2 (en) 2009-04-22
EP2049127B1 (en) 2014-11-26
ES2526713T3 (es) 2015-01-14
WO2007139775A2 (en) 2007-12-06
DK2049127T3 (en) 2015-01-05
US20070281908A1 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
PT2049127E (pt) Derivados n-metanocarba para tratamento de doenças cardíacas
IL209730A0 (en) Triazole derivatives useful for the treatment of diseases
IL200368A0 (en) Treatment of diseases characterized by inflammation
IL210802A0 (en) Purin derivatives for use in the treatment of fab-related diseases
ZA201000075B (en) Purin derivatives for use in the treatment of fab-related diseases
GB0602178D0 (en) Therapeutic treatment
SI2044111T1 (sl) Ciljanje komplementa faktorja H za zdravljenje bolezni
IL196202A0 (en) Indazole derivatives for the treatment of hsp90-induced diseases
IL208357A0 (en) Spiro-indole derivatives for the treatment of parasitic diseases
PT2056863T (pt) Tratamento de doenças oculares
EP2049899A4 (en) METHOD FOR THE PREVENTION AND TREATMENT OF DISEASES
ZA200905364B (en) Treatment of diseases characterized by inflammation
HUE037611T2 (hu) AMP-származékok szívbetegségek kezelésére
EP2148667A4 (en) USE OF CYCLOHEXANHEXOL DERIVATIVES IN THE TREATMENT OF EYE DISEASES
IL202287A0 (en) Therapeutic pyrazolonaphthyridine derivatives
GB0608655D0 (en) Therapeutic Treatment
EP2026822A4 (en) TOPICAL TREATMENT FOR EYE SURGERY DISEASES
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
EP2157089A4 (en) THERAPEUTIC USES OF IMIDAZOL-5-CARBOXYLIC ACID DERIVATIVES
IL213606A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of inflamatory skin diseases
GB0610909D0 (en) Therapeutic treatment
GB2447884B (en) Treatment for skin disease
GB0623740D0 (en) Treatment of disease
PL2160190T3 (pl) Pochodne 5beta, 14beta-androstanu przydatne w leczeniu chorób będących wynikiem zwłóknienia organu
GB0610376D0 (en) Therapeutic treatment